LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
All content for i3 Health Podcast is the property of i3 Health and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2
i3 Health Podcast
27 minutes 10 seconds
3 months ago
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care Module 2 by i3 Health
i3 Health Podcast
LAST CHANCE – Expires November 21!
Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach.
Listen now and earn 0.5 CME credit: bit.ly/49GyP5T
